Skip to main content

Statin effects on atherosclerotic plaques: regression or healing?


Despite the well-documented improved survival of coronary heart disease with the use of statins, their effects on atherosclerotic plaques are not yet fully understood. While some studies suggest statins may reduce plaque volume, the reduction is small even with the use of high-dose statins. Due to this small change in plaque volume, other effects of statin therapy on plaques have been proposed. A large meta-analysis by Banach et al. explored statin effects on plaque composition detected by intravascular ultrasound (IVUS). We discuss the mechanisms of plaque composition modification demonstrated in their study and its implications on atherosclerotic plaque stabilization.

Please see related article:


Since the landmark publication of the 4S trial, which demonstrated improved survival with the use of statins [1], a series of studies have consistently documented a clear reduction of cardiovascular events with statin treatment in different settings. The benefit is clearly associated with important low-density lipoprotein (LDL) cholesterol reduction achieved by this class of drugs; however, their effects on atherosclerotic plaques have not yet been fully elucidated.

Initial magnetic resonance imaging (MRI) studies of the aorta suggested that statin use might result in atherosclerotic plaque regression as early as 6 months after initiation of therapy [2]. These findings were further corroborated by initial data using intravascular ultrasound (IVUS) evaluation of individuals treated with very high-dose statins [3]. The potential regression or reversion of the atherosclerotic process brought significant excitement in the cardiovascular community. Many understood that changes to the atherosclerotic plaque burden could better summarize the whole statin effect on atherosclerosis beyond LDL cholesterol reduction itself, although such changes in plaque volume were limited to 1 % reduction of the plaque burden. Based on the potential advantages of this strategy some authors even suggested that plaque regression should be considered a new target for therapy [4].

Some of this excitement slowly faded away due to two important pieces of evidence. First, the association between plaque burden and incident cardiovascular events did not prove to be true for other classes of drugs. For example, while niacin effectively reduced the carotid intima-media thickness (IMT), a surrogate marker of atherosclerosis [5], this was not translated in any clinical benefit on a larger trial [6]. In contrast, while ezetimibe failed to reduce the carotid IMT in the same study [5], its use resulted in a significant reduction of cardiovascular events beyond baseline statin treatment [7]. Second, while even lower statin doses result in additional reduction in the rate of cardiovascular events, the regression of plaque volume with statins was limited only to subgroups treated with higher doses and longer duration [8].

New insights on the effects of statins on atherosclerotic plaques

A new meta-analysis by Banach et al. [9] reinvestigated the effect of statins on atherosclerosis progression and was recently published in BMC Medicine. The authors included nine studies with more than 830 individuals in whom virtual histology data was available. This study supported previous findings that higher statin doses result in significant plaque volume reduction, while lower statin doses does not. More interestingly, the pooled virtual histology data demonstrated that this small change in plaque volume is a poor summary of plaque composition change. On the one hand, the fibro-fatty and necrotic core volumes remained unchanged with statin use; and on the other hand, a significant fibrous plaque volume reduction accompanied a significant increase in the dense calcium volume. The data also suggests that there is a direct correlation between statin intensity used in each study and the effects on fibrous plaques and on dense calcium volumes, despite the limited power of subgroup analysis. Another very recent meta-analysis reached similar conclusions using different analytical techniques [10].

An interesting aspect of plaque composition derived from the study by Banach et al. is the role of coronary calcification in the atherosclerotic process and its implications on cardiovascular risk assessment. While some authors propose that calcium formation is part of the healing and stabilizing process of atherosclerosis, other in vitro studies indicate that calcium location may better explain the difference in plaque rupture risk [11]. In fact, while clinical studies have firmly documented a direct association between the overall calcification in coronary arteries (measured as either the Agatston score or calcium volume) and cardiovascular events, other studies suggest that the pattern and distribution of calcium in coronary plaques may equally matter. A classical coronary computed tomography (CT) angiography study by Motoyama et al. [12] indicated that small “spotty” calcifications are associated with future plaque ruptures, whereas a sub-analysis of the Multi-Ethnic Study of Atherosclerosis (MESA) study [13] demonstrated that calcium density is inversely associated with events risk. These results, grounded by cellular and molecular data on the mechanisms regulating the pattern of atherosclerotic calcification, suggest that smaller calcium deposition (pro-inflammatory-driven microcalcifications) are associated with plaque rupture and increased cardiovascular risk, while larger, denser calcium structures (anti-inflammatory-driven macrocalcifications) are associated with plaque stabilization and better outcomes, in agreement with the increased dense calcification documented with statin treatment [14].

Collectively, these results indicate that instead of regression, the use of statins can lead to plaque healing and stabilization. The “healed” plaque is only discretely smaller, although it has better structure and is less prone to rupture. Even so, the occurrence of cardiovascular events despite optimized treatment in a significant proportion of patients receiving statins, the so-called “residual risk”, suggests that the healing process is incomplete. In fact, it has been proposed that statins and other preventive measures alter the mechanisms leading to acute coronary syndromes. Instead of plaque rupture, acute coronary syndromes in those “healed” plaques are more likely to occur by erosion. This change is thought to be related to the improved plaque structure associated with the change in its components.


In light of the evidence from the study by Banach et al., future clinical studies using invasive and non-invasive techniques should move forward, with a deeper evaluation of drug effects on atherosclerotic plaques. Instead of absolute quantification of plaque and its components (for example, plaque volume), we should focus on the identification of plaque characteristics or changes in the distribution of plaque components (for example, “spotty” calcification, positive remodeling), as plaques are much more likely to heal and stabilize than to regress.



Computed tomography


Intima-media thickness


Intravascular ultrasound


Low-density lipoprotein


Multi-Ethnic Study of Atherosclerosis


Magnetic resonance imaging


  1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.

    Google Scholar 

  2. Lima JA, Desai MY, Steen H, Warren WP, Gautam S, Lai S. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation. 2004;110:2336–41.

    Article  CAS  PubMed  Google Scholar 

  3. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The asteroid trial. JAMA. 2006;295:1556–65.

    Article  CAS  PubMed  Google Scholar 

  4. Karha J, Bhatt DL. Plaque regression—a new target for antiatherosclerotic therapy. Am Heart J. 2005;149:384–7.

    Article  CAS  PubMed  Google Scholar 

  5. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-release niacin or ezetimibe and carotid intima–media thickness. New Engl J Med. 2009;361:2113–22.

    Article  CAS  PubMed  Google Scholar 

  6. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.

    Article  PubMed  Google Scholar 

  7. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.

    Article  CAS  PubMed  Google Scholar 

  8. Tian J, Gu X, Sun Y, Ban X, Xiao Y, Hu S, et al. Effect of statin therapy on the progression of coronary atherosclerosis. BMC Cardiovasc Disord. 2012;12:70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Banach M. Impact of statin therapy on coronary plaque composition: A systematic review and meta-analysis of virtual histology-intravascular ultrasound studies. BMC Med. 2015;13:229.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Puri R, Nicholls SJ, Shao M, Kataoka Y, Uno K, Kapadia SR, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015;65:1273–82.

    Article  CAS  PubMed  Google Scholar 

  11. Alexopoulos N, Raggi P. Calcification in atherosclerosis. Nat Rev Cardiol. 2009;6:681–8.

    Article  CAS  PubMed  Google Scholar 

  12. Motoyama S, Sarai M, Harigaya H, Anno H, Inoue K, Hara T, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol. 2009;54:49–57.

    Article  PubMed  Google Scholar 

  13. Criqui MH, Denenberg JO, Ix JH, McClelland RL, Wassel CL, Rifkin DE, et al. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA. 2014;311:271–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Pugliese G, Iacobini C, Blasetti Fantauzzi C, Menini S. The dark and bright side of atherosclerotic calcification. Atherosclerosis. 2015;238:220–30.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Marcio Sommer Bittencourt.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

Both authors wrote the initial draft, responded to editorial comments and wrote the final manuscript.

Authors’ information

MSB is an Associate Researcher and attending cardiologist at the Center for Clinical and Epidemiological Research, Division of Internal Medicine at the University Hospital, University of Sao Paulo and serves as Director of Research at the Preventive Medicine Center, Hospital Israelita Albert Einstein. RJC is a cardiologist and Director of Research at Quanta Diagnostico e Terapia.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bittencourt, M.S., Cerci, R.J. Statin effects on atherosclerotic plaques: regression or healing?. BMC Med 13, 260 (2015).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: